Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.
Adrian Paul BanningPatrick SerruysGiovanni Luigi De MariaNicola RyanSimon WalshNieves GonzaloRobert-Jan M van GeunsYoshinobu OnumaManel Sabaté TenasJustin DaviesMaciej LesiakRaul MorenoIgnacio Cruz-GonzalezStephen P HooleJan J PiekClare ApplebyFarzin Fath-OrdoubadiAzfar ZamanNicolas M D A van MieghemNeal UrenJavier ZuecoPawel BuszmanAndres IniguezJavier GoicoleaDavid Hildick-SmithAndrzej OchalaDariusz DudekTon de VriesDavid TaggartVasim FarooqErnest SpitzerJan TijssenJavier EscanedPublished in: European heart journal (2021)
Use of the SYNTAX II PCI strategy in patients with de novo three-vessel disease led to improved and durable clinical results when compared to predefined patients treated with PCI in the original SYNTAX I trial. A predefined exploratory analysis found no significant difference in MACCE between SYNTAX II PCI and matched SYNTAX I CABG patients at 5-year follow-up.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- coronary artery bypass grafting
- acute myocardial infarction
- acute coronary syndrome
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- atrial fibrillation
- clinical trial
- coronary artery
- study protocol
- coronary artery bypass
- randomized controlled trial
- radiofrequency ablation
- phase iii
- ultrasound guided
- open label
- transcatheter aortic valve replacement
- aortic stenosis
- double blind